Ontology highlight
ABSTRACT: Objective
To evaluate the effects of a commonly used combined hormonal oral contraceptive (OC) on carbohydrate metabolism in obese as compared with lean women.Design
6-month prospective study.Setting
Clinical research center at an academic medical center.Patient(s)
Premenopausal nondiabetic women with body mass index <25 kg/m(2) (n = 15) or >30 kg/m(2) (n = 14).Intervention(s)
Ethinyl estradiol (35 ?g) and norgestimate (0.18/0.215/0.25 mg) for 6 cycles.Main outcome measure(s)
Insulin sensitivity by frequent sampling intravenous glucose tolerance test; other indices of insulin sensitivity (homeostatic model assessment of insulin sensitivity index [ISI HOMA], the Matsuda index); fasting lipid panel.Result(s)
Insulin sensitivity changed from 6.62 ± 3.69 min(-1)/mIU/L (baseline) to 8.23 ± 3.30 min(-1)/mIU/L (6 months) in lean women, and from 4.36 ± 2.32 to 3.82 ± 2.32 min(-1)/mIU/L in obese women. Divergent effects on insulin sensitivity were also observed with ISI HOMA and the Matsuda index. Low-density lipoprotein increased by approximately 20 mg/dL in both the lean and obese groups.Conclusion(s)
Lean and obese women exhibit differential changes in insulin sensitivity when given 6 months of a commonly used oral contraceptive. The mechanisms of these differences and whether these divergent effects persist in the long term require further investigation.
SUBMITTER: Cheang KI
PROVIDER: S-EPMC3143285 | biostudies-literature | 2011 Aug
REPOSITORIES: biostudies-literature
Cheang Kai I KI Essah Paulina A PA Sharma Susmeeta S Wickham Edmond P EP Nestler John E JE
Fertility and sterility 20110615 2
<h4>Objective</h4>To evaluate the effects of a commonly used combined hormonal oral contraceptive (OC) on carbohydrate metabolism in obese as compared with lean women.<h4>Design</h4>6-month prospective study.<h4>Setting</h4>Clinical research center at an academic medical center.<h4>Patient(s)</h4>Premenopausal nondiabetic women with body mass index <25 kg/m(2) (n = 15) or >30 kg/m(2) (n = 14).<h4>Intervention(s)</h4>Ethinyl estradiol (35 μg) and norgestimate (0.18/0.215/0.25 mg) for 6 cycles.<h4 ...[more]